AU2001248303A1 - Lipid-based systems for targeting diagnostic agents - Google Patents

Lipid-based systems for targeting diagnostic agents

Info

Publication number
AU2001248303A1
AU2001248303A1 AU2001248303A AU4830301A AU2001248303A1 AU 2001248303 A1 AU2001248303 A1 AU 2001248303A1 AU 2001248303 A AU2001248303 A AU 2001248303A AU 4830301 A AU4830301 A AU 4830301A AU 2001248303 A1 AU2001248303 A1 AU 2001248303A1
Authority
AU
Australia
Prior art keywords
lipid
diagnostic agents
based systems
targeting
targeting diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001248303A
Other languages
English (en)
Inventor
Jesper Davidsen
Sven Frokjaer
Kent Jorgensen
Ole G. Mouritsen
Charlotte Vermehren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liplasome Pharma ApS
Original Assignee
Liplasome Pharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma ApS filed Critical Liplasome Pharma ApS
Publication of AU2001248303A1 publication Critical patent/AU2001248303A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Cosmetics (AREA)
AU2001248303A 2000-04-12 2001-04-11 Lipid-based systems for targeting diagnostic agents Abandoned AU2001248303A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000616 2000-04-12
DKPA200000616 2000-04-12
PCT/DK2001/000269 WO2001076644A2 (en) 2000-04-12 2001-04-11 Lipid-based systems for targeting diagnostic agents

Publications (1)

Publication Number Publication Date
AU2001248303A1 true AU2001248303A1 (en) 2001-10-23

Family

ID=8159422

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001248303A Abandoned AU2001248303A1 (en) 2000-04-12 2001-04-11 Lipid-based systems for targeting diagnostic agents
AU2001248302A Abandoned AU2001248302A1 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems against parasitic infections
AU2001248301A Abandoned AU2001248301A1 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2001248302A Abandoned AU2001248302A1 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems against parasitic infections
AU2001248301A Abandoned AU2001248301A1 (en) 2000-04-12 2001-04-11 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin

Country Status (11)

Country Link
US (4) US7368254B2 (ja)
EP (3) EP1272161B1 (ja)
JP (3) JP2003530338A (ja)
AT (2) ATE336267T1 (ja)
AU (3) AU2001248303A1 (ja)
CY (2) CY1105792T1 (ja)
DE (3) DE60122304T2 (ja)
DK (3) DK1272160T3 (ja)
ES (3) ES2280355T3 (ja)
PT (3) PT1272160E (ja)
WO (3) WO2001076556A2 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
WO2002085391A1 (es) * 2001-04-24 2002-10-31 Luis Alberto Costa Uso de una fosfolipasa a2 para la preparacion de composiciones farmaceuticas y/o cosmeticas para la prevencion y/o el tratamiento local y/o sistemico de enfermedades y/o procesos provocados por patogenos intra y extracelulares que expresen fosfolipidos de membrana
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2338525A3 (en) * 2003-07-09 2011-08-03 California Pacific Medical Center Remote detection of substance delivery to cells
US20050266066A1 (en) * 2003-10-20 2005-12-01 Nof Corporation Phospholipid membrane preparation
WO2005077963A1 (fr) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais DErivEs de saccharides et d'itols possEdant un groupement O-alkyle ou un groupement O-alkyle et un groupement O-n-butanoyle. Applications comme mEdicaments dans les pathologies prolifEratives tumorales ou bEnignes.
US20080113014A1 (en) * 2004-01-28 2008-05-15 Ltt Bio-Pharma Co., Ltd. Method for Screening for Compounds Safe for Gastric Mucosa
DE102004010387A1 (de) * 2004-03-03 2005-09-22 Siemens Ag Kontrastmittel für die Röntgen-Computertomographie
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20070065359A1 (en) * 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
EP1933809B1 (en) * 2005-10-11 2012-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7998945B2 (en) * 2005-12-23 2011-08-16 Jado Technologies Gmbh Methods for the treatment and amelioration of atopic dermatitis
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
WO2011022707A1 (en) 2009-08-21 2011-02-24 Henk-Andre Kroon Vesicular formulations
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
JP2015509507A (ja) * 2012-03-09 2015-03-30 ウニベルシダーヂ フェデラル ヂ ミナス ジェライス−ウエフィエミジェー 内臓リーシュマニア症を治療するための従来型リポソームと長期循環型リポソームを含有する医薬組成物
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
US20140079773A1 (en) * 2012-09-18 2014-03-20 Comfort Care For Animals Llc Encapsulating liposomes
HRP20211669T1 (hr) 2015-06-30 2022-02-18 Sequessome Technology Holdings Limited Multifazni pripravci
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
FR2638639A1 (fr) * 1988-11-08 1990-05-11 Parincos Parfumerie Cosmet Int Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US4874794A (en) * 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
JPH0370491A (ja) 1989-08-04 1991-03-26 Toshiba Corp 電動機制御装置
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US5827836A (en) * 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof

Also Published As

Publication number Publication date
DE60132184T2 (de) 2009-01-15
WO2001076555A3 (en) 2002-03-14
WO2001076644A2 (en) 2001-10-18
ATE382333T1 (de) 2008-01-15
CY1105792T1 (el) 2011-02-02
PT1272160E (pt) 2007-04-30
US20030175205A1 (en) 2003-09-18
CY1106462T1 (el) 2012-01-25
DK1272225T3 (da) 2006-12-27
US7166297B2 (en) 2007-01-23
JP2003530339A (ja) 2003-10-14
DE60126072T2 (de) 2007-11-08
AU2001248301A1 (en) 2001-10-23
DE60122304T2 (de) 2007-08-09
ES2280355T3 (es) 2007-09-16
PT1272225E (pt) 2007-01-31
DK1272160T3 (da) 2007-05-21
WO2001076555A2 (en) 2001-10-18
DE60132184D1 (de) 2008-02-14
ES2295149T3 (es) 2008-04-16
US20030170297A1 (en) 2003-09-11
EP1272160B1 (en) 2007-01-17
DE60122304D1 (de) 2006-09-28
DE60126072D1 (de) 2007-03-08
EP1272225B1 (en) 2006-08-16
WO2001076556A2 (en) 2001-10-18
PT1272161E (pt) 2008-02-08
EP1272225A2 (en) 2003-01-08
WO2001076644A3 (en) 2002-03-14
AU2001248302A1 (en) 2001-10-23
EP1272160A2 (en) 2003-01-08
US7368254B2 (en) 2008-05-06
JP2003530338A (ja) 2003-10-14
ATE336267T1 (de) 2006-09-15
EP1272161B1 (en) 2008-01-02
ES2270991T3 (es) 2007-04-16
US20030162748A1 (en) 2003-08-28
WO2001076556A3 (en) 2002-07-11
US20070134153A1 (en) 2007-06-14
EP1272161A2 (en) 2003-01-08
JP2003530362A (ja) 2003-10-14
DK1272161T3 (da) 2008-05-19

Similar Documents

Publication Publication Date Title
AU2001248303A1 (en) Lipid-based systems for targeting diagnostic agents
GB0222495D0 (en) Compounds
EP1470146B8 (en) Antibodies against the muc18 antigen
ZA987087B (en) Chemical compounds
AU6185398A (en) Charged lipids and uses for the same
HK1088845A1 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
AU3227700A (en) Skin sanitizing compositions
EP2434022A3 (en) Use of A33 antigens and JAM-IT
ECSP055965A (es) Oxatiincarboxamidas
GT200000035AA (es) Derivados de resorcinol, (solicitud fraccionaria no. 1 derivada de la patente pi-2000-0035)
MXPA02003398A (es) Composiciones aromatizantes antimicrobianas.
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
WO2004033660A3 (en) Gene expression profiling from ffpe samples
RS11104A (en) Combined preparations,containing 1,4- benzothiepine-1,1- dioxide derivatives and other active substances, and the use thereof
DE69521122D1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
TR200200278T2 (tr) Kalsilitik bileşimler
DE60041198D1 (de) Antimikrobielle zusammensetzungen
DK0977871T3 (da) Neurotrypsin
NO973666L (no) Kontrastmiddelholdige liposomer for avbildning av det intravaskulære rom
MY130532A (en) Combination of biological and chemical agents to combat rodents
AU2001238470A1 (en) 9-alkylamino-1-nitroacridine derivatives
CA2512952A1 (en) Depigmentation agents
WO2002047697A3 (en) Fractions of snake blood, their preparation and use as therapeutic agents